Opinion of the Transparency Council – sirolimus

At its meeting on 12 September 2022 the Transparency Council adopted opinion No.138/2022 on the inclusion in the reimbursement procedure of medicines containing the active substance sirolimus for the indications for use or posology or route of administration other than those specified in the Summary of Product Characteristics.

Publication in Public Information Bulletin (BIP)